C Cbl (Ab 700) Antibody

Product Specifications

Background

Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.

NCBI Gene ID

867

Swiss Prot

P22681

Accession Number

NP_005179.2

Host

Rabbit

Reactivity

Human

Immunogen

C-Cbl (Ab-700) antibody was raised against a peptide sequence around aa. 698~702 (T-E-Y-M-T) derived from Human c-Cbl.

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Apoptosis, Cancer

Purification

Antibodies were purified by affinity-chromatography using epitope-specific peptide.

Concentration

1 mg/mL

Buffer

Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Store antibody at -20˚ C for up to one year.

Calculated Molecular Weight

120 kDa

Specificity

This antibody detects endogenous level of total c-Cbl protein.

Applications Notes

Western Blot: 1:500~1:1000, Immunohistochemistry: 1:50~1:100

Symbol

CBL

NCBI Official Name

Cbl proto-oncogene, E3 ubiquitin protein ligase

NCBI Organism

Homo sapiens

Background Reference 01

Blake, T. J. et al. (1991) Oncogene 6, 653-657. Thien, C. B. and Langdon, W. Y. (1998) Immunol. Cell Biol. 76, 473-482. Kamei, T. et al. (2000) Int. J. Oncol. 17, 335-339. Hunter, C. et al. (1999) J. Biol. Chem. 274, 2097-2106.

Other Product Names

CBL2, NSLL, C-CBL, RNF55, FRA11B, CSDD2, Signal transduction protein CBL, Proto-oncogene c-CBL, Casitas B-lineage lymphoma proto-oncogene, RING finger protein 55